Streetbeat News

Products Services

NTDOY

Nintendo ADR (OTC:NTDOY) showcased a variety of indie games in their April 2024 Indie World showcase, featuring titles across different genres. Despite missing updates on anticipated games like Hollow Knight: Silksong, the event highlighted new and exclusive indie games, including Little Kitty, Big City, Yars Rising, and more, set to release on various dates throughout the year.

Portfolio Pulse from Franca Quarneti

April 17, 2024 | 8:38 pm

TWKS

Thoughtworks (NASDAQ:TWKS) has acquired technology and talent from Watchful, including a team of seven and co-founders Shayan Mohanty and John Singleton, to enhance its AI and data solutions. This move aims to solidify Thoughtworks' position as a leading AI transformation partner globally. The acquisition will help expedite AI deployment for clients, providing faster returns on AI investments. Watchful's operations will cease, but existing clients will continue to receive support.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:35 pm

TSLA

U.S. Secretary of Transportation Pete Buttigieg emphasized the importance of EV adoption in the U.S., comparing skeptics to those who doubted the transition from landlines to cell phones. Despite recent job cuts at Tesla, Buttigieg highlighted the increasing competition in the EV market, including from Chinese companies, and reiterated the growth in EV sales each year in the U.S. He stressed the need for the U.S. to not fall behind China in EV production and mentioned government support for EV affordability through tax credits. EV sales in the U.S. reached 1.2 million units in 2023, a 46.3% increase from the previous year, with Tesla leading the market.

Portfolio Pulse from Chris Katje

April 17, 2024 | 8:28 pm

ACAD

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced its participation in the 2024 American Academy of Neurology Annual Meeting in Denver, CO, presenting new clinical data on DAYBUE™ (trofinetide) for Rett syndrome. The data includes outcomes from the DAFFODIL™ Phase 2/3 study and caregiver interviews from multiple studies on Rett syndrome treatment with trofinetide. Rett syndrome, a rare neurodevelopmental disorder affecting 5,000-9,000 U.S. patients, shows potential treatment benefits from DAYBUE™, which aims to enhance neuronal synaptic function.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:19 pm

MSOS

Adam Wilks highlighted the importance of supply chain, capitalization, and long-term partnership in selecting Futurola as a perfect fit for their top-shelf, high-end brand. The context suggests a focus on strategic alignment for growth in the cannabis sector, with a nod to the Cannabis Capital Conference for interested subscribers and new users.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:17 pm

MSOS

Ryan Burke discusses the benefits of home growing cannabis, emphasizing education on the growing process and the symbiotic relationship with retail by bringing their genetics to customers' homes. The article also mentions the Cannabis Capital Conference, accessible to subscribers and new users.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:13 pm

EOLS

Evolus, Inc. (NASDAQ:EOLS) announced the publication of Phase 2 study results in the Aesthetic Surgery Journal, demonstrating the safety and 6-month duration of effect of its 'extra-strength' 40U Jeuveau formulation for treating moderate to severe glabellar lines. The study, which compared Jeuveau 40U against two active controls (BOTOX 20U and Jeuveau 20U), showed a similar safety profile across all groups, with the majority of adverse events being mild and no serious adverse events reported. This data was presented at the 2023 ASDS Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:13 pm

AA

Alcoa projects its full-year alumina production to be between 9.8 million and 10 million metric tons, with alumina shipments expected to range from 12.7 million to 12.9 million metric tons.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:12 pm

RLYB

Rallybio Corporation (NASDAQ:RLYB) presented results from a FNAIT systematic literature review and meta-analysis at the AMCP 2024 Annual Meeting, showing a 2.2% HPA-1a negative frequency among nearly 200,000 screened pregnant women. Approximately 33% of these women are at a higher risk for alloimmunization. Rallybio is developing RLYB212, a novel therapy aimed at preventing alloimmunization in pregnant women to mitigate FNAIT risks. The company plans to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:08 pm

MSOS

Adam Wilks highlighted the unique marketing approach of using cannabis meet and greets, noting that 20% of attendees tried cannabis for the first time through this method. This strategy aims to connect consumers with the brand in a novel way. The article also mentions the Cannabis Capital Conference, offering access to both existing and new subscribers.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:05 pm